{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:35:26Z","timestamp":1763552126753},"reference-count":28,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2021]]},"DOI":"10.1620\/tjem.254.57","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T22:43:55Z","timestamp":1622241835000},"page":"57-61","source":"Crossref","is-referenced-by-count":5,"title":["The Effect of Teriparatide for the Treatment of Multiple Spontaneous Clinical Vertebral Fractures after Discontinuation of Denosumab in a Female Patient with Rheumatoid Arthritis: A Case Report"],"prefix":"10.1620","volume":"254","author":[{"given":"Yu","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Izumiyama","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Anastasilakis, A.D., Evangelatos, G., Makras, P. &amp; Iliopoulos, A. (2020)  Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation.  <i>Bone Rep.<\/i>, 12, 100267.","DOI":"10.1016\/j.bonr.2020.100267"},{"key":"2","doi-asserted-by":"publisher","unstructured":"Anastasilakis, A.D., Polyzos, S.A., Makras, P., Trovas, G., Yavropoulou,M.P. &amp; Tournis, S. (2021)  Efficacy of antiosteoporotic medications in patients with rebound-associated fractures after denosumab discontinuation.  <i>J. Clin. Densitom.<\/i>, doi: 10.1016\/j.jocd.2021.01.006.  [Epub ahead of print].","DOI":"10.1016\/j.jocd.2021.01.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bone, H.G., Bolognese, M.A., Yuen, C.K., Kendler, D.L., Miller, P.D., Yang, Y.C., Grazette, L., San Martin, J. &amp; Gallagher, J.C. (2011)  Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.  <i>J. Clin. Endocrinol. Metab.<\/i>, 96, 972-980.","DOI":"10.1210\/jc.2010-1502"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bone, H.G., Bolognese, M.A., Yuen, C.K., Kendler, D.L., Wang, H., Liu, Y. &amp; San Martin, J. (2008)  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.  <i>J. Clin. Endocrinol. Metab.<\/i>, 93, 2149-2157.","DOI":"10.1210\/jc.2007-2814"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Bone, H.G., Wagman, R.B., Brandi, M.L., Brown, J.P., Chapurlat, R., Cummings, S.R., Czerwinski, E., Fahrleitner-Pammer, A., Kendler, D.L., Lippuner, K., Reginster, J.Y., Roux, C., Malouf, J., Bradley, M.N., Daizadeh, N.S., et al.  (2017)  10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.  <i>Lancet Diabetes Endocrinol.<\/i>, 5, 513-523.","DOI":"10.1016\/S2213-8587(17)30138-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Cummings, S.R., San Martin, J., McClung, M.R., Siris, E.S., Eastell, R., Reid, I.R., Delmas, P., Zoog, H.B., Austin, M., Wang, A., Kutilek, S., Adami, S., Zanchetta, J., Libanati, C., Siddhanti, S., et al.  (2009)  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.  <i>N. Engl. J. Med.<\/i>, 361, 756-765.","DOI":"10.1056\/NEJMoa0809493"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Florez, H., Ramirez, J., Monegal, A., Guanabens, N. &amp; Peris, P. (2019)  Spontaneous vertebral fractures after denosumab discontinuation: a case collection and review of the literature.  <i>Semin. Arthritis Rheum.<\/i>, 49, 197-203.","DOI":"10.1016\/j.semarthrit.2019.02.007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Girotra, M., Rubin, M.R. &amp; Bilezikian, J.P. (2006)  The use of parathyroid hormone in the treatment of osteoporosis.  <i>Rev. Endocr. Metab. Disord.<\/i>, 7, 113-121.","DOI":"10.1007\/s11154-006-9007-z"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Kamimura, M., Mori, Y., Sugahara-Tobinai, A., Takai, T. &amp; Itoi, E. (2015)  Impaired fracture fealing caused by deficiency of the immunoreceptor adaptor protein DAP12.  <i>PLoS One<\/i>, 10, e0128210.","DOI":"10.1371\/journal.pone.0128210"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Kashii, M., Ebina, K., Kitaguchi, K. &amp; Yoshikawa, H. (2020)  Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report.  <i>Bone Rep.<\/i>, 13, 100288.","DOI":"10.1016\/j.bonr.2020.100288"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Lamy, O., Stoll, D., Aubry-Rozier, B. &amp; Rodriguez, E.G. (2019)  Stopping denosumab.  <i>Curr. Osteoporos. Rep.<\/i>, 17, 8-15.","DOI":"10.1007\/s11914-019-00502-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Leder, B.Z., Tsai, J.N., Uihlein, A.V., Wallace, P.M., Lee, H., Neer, R.M. &amp; Burnett-Bowie, S.-A.M. (2015)  Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.  <i>Lancet<\/i>, 386, 1147-1155.","DOI":"10.1016\/S0140-6736(15)61120-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"McClung, M.R. (2016)  Cancel the denosumab holiday.  <i>Osteoporos. Int.<\/i>, 27, 1677-1682.","DOI":"10.1007\/s00198-016-3553-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Mognetti, B., Marino, S., Barberis, A., Martin, A.S., Bala, Y., Di Carlo, F., Boivin, G. &amp; Barbos, M.P. (2011)  Experimental stimulation of bone healing with teriparatide: histomorphometric and microhardness analysis in a mouse model of closed fracture.  <i>Calcif. Tissue Int.<\/i>, 89, 163-171.","DOI":"10.1007\/s00223-011-9503-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Mori, Y., Izumiyama, T., Baba, K., Mori, N., Fujii, H., Ishii, T. &amp; Itoi, E. (2020)  Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis.  <i>J. Orthop. Surg. Res.<\/i>, 15, 290.","DOI":"10.1186\/s13018-020-01813-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Mori, Y., Izumiyama, T., Kurishima, H., Kamimura, M., Baba, K., Mori, N. &amp; Itoi, E. (2021)  Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies.  <i>J. Orthop. Surg. Res.<\/i>, 16, 107.","DOI":"10.1186\/s13018-021-02271-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Mori, Y., Kuwahara, Y., Chiba, S., Kogre, A., Baba, K., Kamimura, M. &amp; Itoi, E. (2017)  Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment.  <i>J. Bone Miner. Metab.<\/i>, 35, 52-57.","DOI":"10.1007\/s00774-015-0716-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Prince, R., Gaich, G.A., Reginster, J.Y., Hodsman, A.B., Eriksen, E.F., Ish-Shalom, S., Genant, H.K., Wang, O. &amp; Mitlak, B.H. (2001)  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.  <i>N. Engl. J. Med.<\/i>, 344, 1434-1441.","DOI":"10.1097\/00006254-200110000-00018"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Niimi, R., Kono, T., Nishihara, A., Hasegawa, M., Kono, T. &amp; Sudo, A. (2020)  Second rebound-associated vertebral fractures after denosumab discontinuation.  <i>Arch. Osteoporos.<\/i>, 15, 7.","DOI":"10.1007\/s11657-019-0676-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Ominsky, M.S., Li, C., Li, X., Tan, H.L., Lee, E., Barrero, M., Asuncion, F.J., Dwyer, D., Han, C.Y., Vlasseros, F., Samadfam, R., Jolette, J., Smith, S.Y., Stolina, M., Lacey, D.L., et al.  (2011)  Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.  <i>J. Bone Miner. Res.<\/i>, 26, 1012-1021.","DOI":"10.1002\/jbmr.307"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Papapoulos, S., Lippuner, K., Roux, C., Lin, C.J., Kendler, D.L., Lewiecki, E.M., Brandi, M.L., Czerwinski, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J.Y., Jensen, S., Daizadeh, N.S., et al.  (2015)  The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.  <i>Osteoporos. Int.<\/i>, 26, 2773-2783.","DOI":"10.1007\/s00198-015-3234-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Saag, K.G., Pannacciulli, N., Geusens, P., Adachi, J.D., Messina, O.D., Morales-Torres, J., Emkey, R., Butler, P.W., Yin, X. &amp; Lems, W.F. (2019)  Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial.  <i>Arthritis Rheumatol.<\/i>, 71, 1174-1184.","DOI":"10.1002\/art.40874"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Saito, M., Marumo, K., Kida, Y., Ushiku, C., Kato, S., Takao-Kawabata, R. &amp; Kuroda, T. (2011)  Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys.  <i>Osteoporos. Int.<\/i>, 22, 2373-2383.","DOI":"10.1007\/s00198-010-1454-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Saito, M., Marumo, K., Soshi, S., Kida, Y., Ushiku, C. &amp; Shinohara, A. (2010)  Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia.  <i>Osteoporos. Int.<\/i>, 21, 655-666.","DOI":"10.1007\/s00198-009-0980-4"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Taguchi, A., Uemura, Y., Imai, T., Tanaka, S., Ohta, H., Nakamura, T., Orimo, H., Sugimoto, T., Soen, S., Shiraki, M. &amp; Adequate Treatment of Osteoporosis research, g. (2019)  Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid.  <i>J. Bone Miner. Metab.<\/i>, 37, 886-892.","DOI":"10.1007\/s00774-019-00990-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Takeuchi, T., Tanaka, Y., Ishiguro, N., Yamanaka, H., Yoneda, T., Ohira, T., Okubo, N., Genant, H.K. &amp; van der Heijde, D. (2016)  Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.  <i>Ann. Rheum. Dis.<\/i>, 75, 983-990.","DOI":"10.1136\/annrheumdis-2015-208052"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Tripto-Shkolnik, L., Liel, Y., Yekutiel, N. &amp; Goldshtein, I. (2021)  Long-term follow-up of denosumab discontinuers with multiple vertebral fractures in the real-world: a case series.  <i>Horm. Metab. Res.<\/i>, 53, 185-190.","DOI":"10.1055\/a-1368-4218"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Yoneda, T., Hagino, H., Sugimoto, T., Ohta, H., Takahashi, S., Soen, S., Taguchi, A., Toyosawa, S., Nagata, T. &amp; Urade, M. (2010)  Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.  <i>J. Bone Miner. Metab.<\/i>, 28, 365-383.","DOI":"10.1007\/s00774-010-0162-7"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/254\/1\/254_57\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T03:13:10Z","timestamp":1623381190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/254\/1\/254_57\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.254.57","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}